Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Q4 2019 Earnings Conference Call - Final Transcript
Mar 12, 2020 • 05:00 pm ET
Greetings, and welcome to the Bellicum Pharmaceuticals Fourth Quarter and Full-Year 2019 Financial Results and Corporate Update Conference Call. [Operator Instructions]
I would now like to turn the conference over to your host, Mr. Stephen Jasper from Westwicke ICR. Please go ahead, sir.
Thank you. Good afternoon, everyone, and thank you for joining the call. With me today on the call is Rick Fair, Bellicum's President and Chief Executive Officer; and Atabak Mokari, Chief Financial Officer. Later, during the Q&A session, Aaron Foster, Head of Research will also be available.
Earlier this afternoon, Bellicum released financial results for the fourth quarter and full-year ended December 31st, 2019. If you have not received this release or if you would like to be added to the distribution list, you can do so on the Investor Relations page of the company's website.
As a reminder, today's conference call will include forward-looking statements made under the Private Securities Litigation Reform Act of 1995, including statements regarding our research and development plans, clinical trials, plans regarding regulatory filings, review and approval of our product candidates, commercialization expectations and our financial outlook. These forward-looking statements involve a number of risks and uncertainties and reflect our opinions only as of the date of this call. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events.
Actual results may differ from those indicated by these forward-looking statements, due to numerous factors, including those discussed in the Risk Factors section of our Form 10-K for the year ended December 31st, 2019, filed with the Securities and Exchange Commission.
And now I will turn the call over to Rick Fair, Bellicum's President and CEO.
Thanks, Stephen. Good afternoon, everyone, and thanks for joining us today. On our call, I'll provide an update on our GoCAR platform and our programs and two recently announced corporate transactions.
As a reminder, our GoCAR platform is differentiated in two distinct ways. First, we've engineered GoCAR with the goal to deliver more potent and durable efficacy relative to current generation CAR-T. This is accomplished primarily through our coactivation domain, MyD88, CD40 or MC. MC signaling is believed to boost effector cell proliferation and survival to enhance functional persistence by resisting exhaustion and the suppressive tumor microenvironment and to stimulate the cancer patient's own immune system.
Second, we've engineered GoCAR for higher performance, providing enhanced control with our switch technology. Other CAR therapies behave unpredictably, due to their autonomous activity, but GoCAR antitumor effects are controlled by the scheduled administration of rimiducid. GoCAR activity can be modulated by adjusting the interval between rimiducid doses.
In our dual-switch product candidates, we further improved controllability by incorporating our CaspaCIDe safety switch, which is designed to rapidly eliminate cells when triggered to manage acute toxicities if they occur. As the next-generation CAR platform, we believe GoCAR may address many of the shortcomings of current cell therapies. We've demonstrated some of these potential benefits in